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Abstract
Systemic sclerosis (SSc) is a fibrotic autoimmune disease in which the genetic component plays an important role. One of
the strongest SSc association signals outside the human leukocyte antigen (HLA) region corresponds to interferon (IFN)
regulatory factor 5 (IRF5), a major regulator of the type I IFN pathway. In this study we aimed to evaluate whether three
different haplotypic blocks within this locus, which have been shown to alter the protein function influencing systemic
lupus erythematosus (SLE) susceptibility, are involved in SSc susceptibility and clinical phenotypes. For that purpose, we
genotyped one representative single-nucleotide polymorphism (SNP) of each block (rs10488631, rs2004640, and rs4728142)
in a total of 3,361 SSc patients and 4,012 unaffected controls of Caucasian origin from Spain, Germany, The Netherlands,
Italy and United Kingdom. A meta-analysis of the allele frequencies was performed to analyse the overall effect of these IRF5
genetic variants on SSc. Allelic combination and dependency tests were also carried out. The three SNPs showed strong
associations with the global disease (rs4728142: P = 1.3461028, OR = 1.22, CI 95% =1.14–1.30; rs2004640: P = 4.6061027,
OR = 0.84, CI 95% = 0.78–0.90; rs10488631: P = 7.53610220, OR = 1.63, CI 95% =1.47–1.81). However, the association of
rs2004640 with SSc was not independent of rs4728142 (conditioned P = 0.598). The haplotype containing the risk alleles
(rs4728142*A-rs2004640*T-rs10488631*C: P = 9.04610222, OR = 1.75, CI 95% =1.56–1.97) better explained the observed
association (likelihood P-value = 1.4861024), suggesting an additive effect of the three haplotypic blocks. No statistical
significance was observed in the comparisons amongst SSc patients with and without the main clinical characteristics. Our
data clearly indicate that the SLE risk haplotype also influences SSc predisposition, and that this association is not sub-
phenotype-specific.
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Introduction
Systemic sclerosis (SSc) is a chronic multisystem connective
tissue disorder characterized by fibrotic events, vascular damage
and autoantibody production. Two main clinical subtypes have
been defined based on the extent of skin involvement, limited
cutaneous scleroderma (lcSSc) and diffuse cutaneous scleroderma
(dcSSc) [1]. Recent candidate gene and genome-wide association
studies (GWASs) clearly suggest that an important genetic
component underlies this disease. In this regard, an increasing
number of loci have been reported to be convincingly associated
with the susceptibility and clinical manifestations of SSc in the last
years. However, the causal functional mutations responsible for
these associations have not been unambiguously identified yet in
most cases [2].
Outside the HLA region, interferon (IFN) pathway genes, which
encode cytokines with critical modulatory effects on innate and
adaptive immunity, have been shown to represent a key
component of the genetic network leading to autoimmune
processes. Interestingly, a misregulated expression of type I IFN
genes, also referred to as IFN signature, have been observed in
peripheral white blood cells patient subsets of several autoimmune
diseases [3,4,5,6], thus suggesting that the IFN signaling plays a
crucial role in autoimmunity. Indeed, multiple single-nucleotide
polymorphisms (SNPs) of the IFN regulatory factor 5 gene (IRF5),
a major regulator of the type I IFN induction, have been
associated with different rheumatic disorders such as SSc, systemic
lupus erythematosus (SLE), rheumatoid arthritis (RA), and
Sjo¨gren’s syndrome (SS) [7,8,9,10]. The IRF5 association with
SLE was narrowed down to three different haplotype blocks that
seem to have independent functional consequences, including 1)
alteration of the protein stability, 2) creation of a donor splice site
in intron 1 resulting in transcription of an alternative exon 1B, and
3) modification of the 39UTR length which affects expression
levels [11]. Subsequent studies in SSc patients suggested that
genetic variation within IRF5 correlate with SSc severity and
survival [12,13].
Based on the above, we decided to explore whether the
functional haplotype blocks described by Graham et al. [11] were
also susceptibility signals affecting SSc development and progres-
sion. For that purpose, we analysed the allele frequencies of three
representative IRF5 genetic variants that have been previously
associated with SSc [8,14] in five large Caucasian European
cohorts and performed allelic combination and dependency tests.
Patients and Methods
Study Population
We recruited a total of 3,361 SSc patients and 4,012 unaffected
controls of Caucasian origin from five different European
countries, including an initial cohort from Spain and four
replication cohorts from Germany, The Netherlands, Italy and
United Kingdom. Case and control sets were matched by
geographical origin and ethnicity. Written informed consent from
all participants and approval from the local ethical committees of
all centres involved in the study were obtained in accordance with
the tenets of the Declaration of Helsinki. All SSc patients fulfilled
the classification criteria by Leroy et al. [15]. The clinical features
of the different SSc cohorts are shown in Table 1. Case sets were
further subdivided based on their skin involvement into limited
cutaneous scleroderma (lcSSc) and diffuse cutaneous scleroderma
(dcSSc) subgroups [15], and by autoantibody status according to
the presence/absence of anti-centromere antibodies (ACA) or anti-
topoisomerase antibodies (ATA), which were detected using
standard procedures. Pulmonary fibrosis (PF) was diagnosed by
high resolution computed tomography (HRCT).
SNPs Selection and Genotyping
Samples were genotyped for three IRF5 tag SNPs, rs10488631,
rs2004640, and rs4728142, representative of three different
haplotype blocks (refers to as Groups 1–3, respectively) which
have been reported to have functional roles in SLE patients [11]:
Group 1 includes SNPs tagging a 30-bp in-frame INDEL variant
of exon 6 that alters protein stability; Group 2 includes an exon 1B
splice site variant; and Group 3 corresponds to genetic variants
located in a conserved polyadenilation signal sequence that alters
the length of the 39UTR, thus affecting expression levels.
Genomic DNA was obtained from peripheral blood cells using
standard procedures, and genotyping was performed using
TaqManH 59 allele discrimination assays (IDs: C___2691242_10,
C___9491614_10, and C___2691222_10), in a 7900 HT Fast
Real-Time PCR System (Applied Biosystems, Foster City,
California, USA).
Statistical Analysis
The statistical power of the study was calculated with Power
Calculator for Genetic Studies 2006 software (http://www.sph.
umich.edu/csg/abecasis/CaTS/reference.html), which implements
the methods described in Skol et al. [16].
Table 1. Main clinical features of systemic sclerosis patients
included in the study.
N (%)
Feature Spain Germany Netherlands Italy UK
Female 1089 (89.14) 494 (85.83) 323 (81.83) 644 (91.50) 388 (83.33)
Male 133 (10.86) 81 (14.17) 72 (18.17) 60 (8.50) 77 (16.67)
lcSSc 843 (68.99) 338 (58.78) 271 (68.61) 515 (73.15) 336 (72.26)
dcSSc 379 (31.01) 237 (41.22) 124 (31.39) 189 (26.85) 129 (27.74)
ACA+ 560 (45.83) 214 (37.22) 99 (25.06) 312 (44.32) 169 (36.34)
ACA- 617 (50.49) 341 (59.30) 291 (73.67) 385 (54.69) 285 (61.29)
ATA+ 267 (21.85) 174 (30.26) 106 (26.84) 238 (33.81) 71 (15.27)
ATA- 881 (72.09) 376 (65.39) 284 (71.90) 461 (65.48) 382 (82.15)
PF+ 294 (24.06) 175 (30.43) 144 (36.46) 205 (29.12) 111 (23.87)
PF- 830 (67.92) 327 (56.87) 158 (40.00) 400 (56.82) 189 (40.65)
Data are referred to the total analysed individuals.
ACA; anti-centromere antibodies; ATA, anti-topoisomerase antibodies; dcSSc,
difusse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis;
PF, pulmonary fibrosis.
doi:10.1371/journal.pone.0054419.t001
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PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/)
[17] was used to carried out all statistical analyses of allele
frequencies. P-values were obtained by performing 262 contin-
gency tables and x2 test and/or Fisher’s exact test, when
appropriate. Since the association between IRF5 and SSc has
been confirmed in several independent studies [2], we considered
appropriate to set the significance threshold at P = 0.05. Odds
ratios (OR) and 95% confidence intervals were calculated
according to Woolf’s method. Breslow–Day (BD) test method
was used to estimate the homogeneity amongst populations.
Pooled analyses were performed by Mantel-Haenszel test under
fixed effects, or DerSimonian-Laird if the BD test reached
statistical significance.
Dependency of association between the studied genetic variants
was determined by conditional logistic regression analysis as
implemented in PLINK, and the allelic combinations were tested
using PLINK, StatsDirect (V.2.6.6; StatsDirect, Altrincham, UK),
and Haploview (V.4.2) [18].
To analyse whether allelic combinations would better explained
the possible association than the genetic variants independently,
we compared the goodness of fit of both models using PLINK. For
that purpose, we calculated the deviance (defined as 226 the log
likelihood), which follows a x2 distribution, to assess the
significance of the improvement in fit. If statistically significant
differences in the improvement of fit were observed when the
haplotype effect was considered, we assumed that this model was
more informative explaining the putative association.
Results
The overall statistical power of the study, based on previous
IRF5 reports, to detect associations with OR = 1.2 at 0.05
significance level was 100% for rs2004640 and rs4728142, and
93% for rs10488631 (Table S1 in File S1). Additionally, no
significant departure from Hardy-Weinberg equilibrium was
observed either in cases or controls in each analysed population
(P = 0.05).
Allele Test
The results of the global analyses of the discovery cohort and the
four independent replication populations separately are shown in
Table S2 in File S1. Since the Breslow-Day test evidenced no
heterogeneity of the ORs amongst the different cohorts (P = 0.05),
a combined meta-analysis was performed to test the overall effect
of the IRF5 genetic variants in the whole dataset (Table 2). The
pooled analysis showed that the three SNPs were strongly
associated with the global disease (rs4728142: P = 1.3461028,
OR = 1.22, CI 95% = 1.14–1.30; rs2004640: P = 4.6061027,
OR = 0.84, CI 95% = 0.78–0.90; rs10488631: P = 7.53610220,
OR = 1.63, CI 95% = 1.47–1.81). Highly significant P-values
were also yielded when the different phenotype subgroups were
compared against the control population (Table S3 in File S1).
However, no statistical significance was observed in the compar-
isons amongst SSc patients accordingly with the presence/absence
of the different clinical characteristics and autoantibody profile
(Table 2), i.e. lcSSc vs. dcSSc (rs4728142: P = 0.564; rs2004640:
P = 0.971; rs10488631: P = 0.086), SSc ACA+ vs. SSc ACA-
(rs4728142: P = 0.359; rs2004640: P = 0.357; rs10488631: P
= 0.449), SSc ATA+ vs. SSc ATA- (rs4728142: P = 0.154;
rs2004640: P = 0.128; rs10488631: P = 0.259), and SSc PF+ vs.
SSc PF- (rs4728142: P = 0.934; rs2004640: P = 0.397;
rs10488631: P = 0.945), thus indicating the three IRF5 polymor-
phisms are indeed associated with the global disease and there was
no phenotype-specific association.
Conditional Logistic Regression
We decided to perform pairwise conditioning analyses to test
whether there could be any dependency amongst them (Table 3).
The analysis showed that every SNP maintained its statistical
significance after conditioning to the other two except for
rs2004640, which was dependent of rs4728142. The moderate
linkage disequilibrium between them (r2,0.68) could explain this
fact (Table S4 in File S1).
Haplotype Analysis
We also analysed the allelic combinations of the IRF5 genetic
variants included in this study according to the global disease
(Table 4). The most associated haplotype was that containing the
risk alleles of the three SNPs (rs4728142*A-rs2004640*T-
rs10488631*C: P = 9.04610222, OR = 1.75, CI 95% = 1.56–
1.97). The protective haplotype also showed a very significant
P-value (rs4728142*G-rs2004640*G-rs10488631*T: P = 2.4861027,
OR = 0.84, CI 95% = 0.78–0.89).
When comparing the haplotype model with the independent
SNP model, we observed a statistically significant improvement of
the goodness of fit compared to rs4728142 (likelihood P-value =
1.23610217), rs2004640 (likelihood P-value = 1.94610219), or
rs10488631 (likelihood P-value = 1.4861024) individually.
On the other hand, we also performed a sub-phenotype analysis
of allelic combinations to test whether some haplotype could
influence a specific clinical condition (Table S5 in File S1). This
analysis only showed a residual P-value for a low frequency
haplotype in the PF+/PF- comparison (rs4728142*G-
rs2004640*T-rs10488631*T: P = 0.041, OR = 1.28, CI 95% =
1.02–1.61). The rest of allelic combinations did not reach statistical
significance in any other comparison.
Discussion
GWAS data have confirmed IRF5 as one of the strongest
associated signals with SSc [19,20]. In addition, it has been
proposed that particular IRF5 functional genetic elements
contribute to SLE pathophysiology through their relationship
with auto-antibodies and IFNa production [21,22]. These data
indicate that this gene may represent a crucial member of the
genetic component underlying this type of autoimmune diseases
[23].
Previous published data suggested that two different IRF5
haplotypes influence specific SSc phenotypes. It was hypothesised
that these haplotypes may explain a possible IRF5 association with
dcSSc and PF, likely by tagging an intronic 5-bp biallelic insertion-
deletion polymorphism (INDEL), which would represent the real
causal functional variant [12]. However, our results are not in
agreement with this idea, since we did not find evidence for a
specific genetic association between IRF5 and any of the major
clinical manifestations, despite the fact that two out of the three
genetic variants comprising the previously described risk haplotype
were covered in our analysis (rs2004640 and rs10954213 that is
highly correlated with rs4728142). A similar discrepancy was also
observed by Sarif et al. [13], who failed to replicate the IRF5
haplotype effect on PF described by Dieude´ et al. [12]. Our data
are, however, consistent with recent GWAS follow-up studies that
did not show a phenotype-specific association of IRF5 with SSc,
but a clear association with the overall disease [14,24]. It should be
noted that one of the SNPs included in this study, rs4728142, has
been shown to correlate with longer survival and a milder
pulmonary involvement in SSc patients [13]. Taking this together
with our results, it could be speculated that, although the risk
variants of IRF5 do not predispose to develop PF, they may
IRF5 in Systemic Sclerosis
PLOS ONE | www.plosone.org 3 January 2013 | Volume 8 | Issue 1 | e54419
influence the severity of some clinical features like PF. In any case,
it is important to note that whereas antibody profile and disease
subtypes are clearly a dichotomous outcome, PF can range from
mild-stable to severe-progressive involvement (and the utilised
approach for definition of PF does not differentiate the different
severity scales of this disease manifestation) [25].
Table 2. Meta-analysis of IRF5 genetic variants accordingly with the global disease and the presence or absence of the main
clinical features.
Genotype, N (%) M-H allele test
SNP Position 1/2 Subgroup (N) 1/1 1/2 2/2 MAF (%) P-value OR [CI 95%]{ PBD
"
rs4728142 39UTR A/G Controls (n = 3933) 787 (20.01) 1924 (48.92) 1222 (31.07) 44.47 1.34E-08 1.22 [1.14–1.30] 0.32
SSc (n = 3128) 769 (24.58) 1549 (49.52) 810 (25.90) 49.34
lcSSc (n = 2142) 533 (24.88) 1059 (49.44) 550 (25.68) 49.60 0.564 0.97 [0.87–1.08] 0.61
dcSSc (n = 986) 236 (23.94) 490 (49.70) 260 (26.37) 48.78
ACA- (n = 1781) 444 (24.93) 852 (47.84) 485 (27.23) 48.85 0.359 1.05 [0.95–1.16] 0.08
ACA+ (n = 1268) 307 (24.21) 658 (51.89) 303 (23.90) 50.16
ATA- (n = 2222) 531 (23.90) 1110 (49.95) 581 (26.15) 48.87 0.154 1.09 [0.97–1.22] 0.28
ATA+ (n = 793) 215 (27.11) 378 (47.67) 200 (25.22) 50.95
PF- (n = 1797) 427 (23.76) 929 (51.70) 441 (24.54) 49.61 0.934 1.00 [0.89–1.12] 0.97
PF+ (n = 893) 237 (26.54) 409 (45.80) 247 (27.66) 49.44
rs2004640 Exon 1 G/T Controls (n = 3912) 897 (22.93) 1895 (48.44) 1120 (28.63) 47.15 4.60E-07 0.84 [0.78–0.90] 0.12
SSc (n = 3122) 584 (18.71) 1511 (48.40) 1027 (32.90) 42.91
lcSSc (n = 2143) 406 (18.95) 1026 (47.88) 711 (33.18) 42.88 0.971 1.00 [0.90–1.12] 0.23
dcSSc (n = 979) 178 (18.18) 485 (49.54) 316 (32.28) 42.95
ACA- (n = 1772) 354 (19.98) 833 (47.01) 585 (33.01) 43.48 0.357* 0.91 [0.74–1.12] 0.01
ACA+ (n = 1272) 211 (16.59) 643 (50.55) 418 (32.86) 41.86
ATA- (n = 2216) 424 (19.13) 1076 (48.56) 716 (32.31) 43.41 0.128 0.91 [0.81–1.03] 0.43
ATA+ (n = 793) 137 (17.28) 377 (47.54) 279 (35.18) 41.05
PF- (n = 1800) 327 (18.17) 899 (49.94) 574 (31.89) 43.14 0.397 0.95 [0.85–1.07] 0.84
PF+ (n = 883) 163 (18.46) 417 (47.23) 303 (34.31) 42.07
rs10488631 INDEL tagger C/T Controls (n = 3958) 41 (1.04) 625 (15.79) 3292 (83.17) 8.93 7.53E-20 1.63 [1.47–1.81] 0.11
SSc (n = 3148) 70 (2.22) 749 (23.79) 2329 (73.98) 14.12
lcSSc (n = 2165) 46 (2.12) 494 (22.82) 1625 (75.06) 13.53 0.086 1.14 [0.98–1.33] 0.96
dcSSc (n = 983) 24 (2.44) 255 (25.94) 704 (71.62) 15.41
ACA- (n = 1798) 48 (2.67) 425 (23.64) 1325 (73.69) 14.49 0.449 0.94 [0.81–1.10] 0.92
ACA+ (n = 1273) 21 (1.65) 306 (24.04) 946 (74.31) 13.67
ATA- (n = 2236) 48 (2.15) 508 (22.72) 1680 (75.13) 13.51 0.259* 1.17 [0.89–1.54] 0.03
ATA+ (n = 799) 21 (2.63) 212 (26.53) 566 (70.84) 15.89
PF- (n = 1818) 43 (2.37) 425 (23.38) 1350 (74.26) 14.05 0.945 0.99 [0.84–1.17] 0.94
PF+ (n = 886) 19 (2.14) 213 (24.04) 654 (73.81) 14.16
{Odds ratio for the minor allele.
"Breslow-Day P-value.
*DerSimonian–Laird random effects model P-value. SSc, systemic sclerosis; lcSSc, limited cutaneous SSc; dcSSc, diffuse cutaneous SSc; ACA, anti-centromere antibodies;
ATA, anti-topoisomerase antibodies. M-H, Mantel-Haenszel test under fixed effect.
doi:10.1371/journal.pone.0054419.t002
Table 3. Conditional logistic regression analysis for the IRF5 polymorphisms considering the five populations as covariate.
SNP P-value
P-value:
add to rs10488631
rs10488631 P-value:
add to SNP
P-value:
add to rs2004640
rs2004640 P-value:
add to SNP
rs4728142 1.344E-08 2.57E-04 8.92E-16 2.24E-03 0.598
rs2004640 4.603E-07 0.020 1.72E-16 NA NA
rs10488631 7.528E-20 NA NA 1.72E-16 0.020
LD, linkage disequilibrium; SNP, single-nucleotide polymorphism.
doi:10.1371/journal.pone.0054419.t003
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As stated before, the tag SNPs analysed here are representative
of three haplotype blocks that have been reported to affect the
function of the protein in different ways, including production of
an alternative spliced isoform, alteration of polyadenylation sites
that leads to a shorter messenger RNA, and reduction of protein
stability [11]. These three polymorphisms showed strong associ-
ation signals in our study, supported by a high statistical power.
Therefore, the functional alterations caused by their risk alleles
may be also of high relevance in the pathogenic mechanisms that
lead to SSc. However, the rs2004640 signal was dependant of that
from rs4728142 in our study cohort. Hence, rs2004640 might not
be an independent SSc susceptibility locus although it is
functionally relevant, which suggests that not all functional
variants in a determined risk gene may play an independent role
in the associated disease. In any case, as described in SLE [11], we
observed a significant additive effect amongst the three analysed
SNPs because the haplotypes containing both the risk and
protective alleles better explained the association between this
locus and SSc. Hence, although no functional studies have been
carried out yet to unmask the possible implication of the IRF5 risk
alleles in the SSc pathophysiology, it is likely that each one of the
protein alterations described above influence the development of
SSc individually, and that carrying all the three risk alleles results
in a critically reduced protein function that highly increases SSc
susceptibility.
In conclusion, this study clearly shows that a haplotype of three
different functional genetic variants within the IRF5 region confer
susceptibility to SSc. The fact that this association is shared with
SLE adds another piece of evidence to the common genetic
background of both diseases, and provides a new perspective for
the study of the type I IFN pathway and its implication in the
development of autoimmune conditions.
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